Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...
Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy Kaftrio. Read more here.
The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...
Verve Therapeutics remains a high-reward investment despite setbacks. Click here to find out why VERV stock is a Buy.
The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine), an oral NaV1.8 inhibitor, as a treatment for acute pain, representing ...